IEDB

Carol — Tue, 08 Sep 2026 20:30:13 GMT

Population Coverage of a SARS-CoV2 Peptide Vaccine

← Older revision		Revision as of 22:30, 8 September 2026
(One intermediate revision by the same user not shown)
Line 72:		Line 72:

	Start refining your search using the search fields on the left of the results page. In the ’Organism’ box of		Start refining your search using the search fields on the left of the results page. In the ’Organism’ box of
	the ~~’Antigen’~~ field search for ’Ebolavirus (ID:186538, ID:186539, ID:186540, ID:186541)’. You can also try searching for ’Ebolavirus’ in the		the ’Epitope Source’ field search for ’Ebolavirus (ID:186538, ID:186539, ID:186540, ID:186541)’. You can also try searching for ’Ebolavirus’ in the
	organism finder in the ~~’Antigen’~~ field. Click ’Search’ (Top Left) again to add this filter.		organism finder in the ’Epitope Source’ field. Click ’Search’ (Top Left) again to add this filter.

	*'''Q11: How many Ebola virus epitopes do you see?'''		*'''Q11: How many Ebola virus epitopes do you see?'''
Line 82:		Line 82:
	*'''Q12: How many Human reactive Ebola virus epitopes results do you see?'''		*'''Q12: How many Human reactive Ebola virus epitopes results do you see?'''

	Now, let’s filter the ~~ebola~~ epitope set down to only epitopes that have been positively shown to result in		Now, let’s filter the Ebola epitope set down to only epitopes that have been positively shown to result in
	neutralization in a human host. In the ~~’Assay’~~ search field, select ~~the ’B Cell Assay’ finder. In the assay~~		neutralization in a human host. In the ’B cell assay’ search field, select ’Neutralization’, and then 'Search' to add this
	~~finder, expand the ’Biological Activity’ folder and click~~ ’Neutralization’, ~~’Apply’~~ and then ~~search~~ to add this
	last filter.		last filter.

Line 105:		Line 104:
	We have all been influenced by the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Fortunately, vaccines have been developed and approved in record time. The currently approved mRNA vaccines of Pfizer and Moderna code for the SARS-CoV-2 Spike Protein, a viral fusion protein that is important for cell adhesion and the induction of protective immunity.		We have all been influenced by the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Fortunately, vaccines have been developed and approved in record time. The currently approved mRNA vaccines of Pfizer and Moderna code for the SARS-CoV-2 Spike Protein, a viral fusion protein that is important for cell adhesion and the induction of protective immunity.

	This and the next exercise ~~will be reminiscent of~~ the HCV vaccine development exercise, but we will work with tools from the IEDB and target the SARS-CoV2 spike protein. Here we want to investigate the importance of population coverage in rational peptide vaccine design. To this end, we will work with data from the IEDB and use the Population Coverage Analysis Tool.		This and the next exercise is linked to the HCV vaccine development exercise, but we will work with tools from the IEDB and target the SARS-CoV2 spike protein. Here we want to investigate the importance of population coverage in rational peptide vaccine design. To this end, we will work with data from the IEDB and use the Population Coverage Analysis Tool.

	From the IEDB home page, search for MHC I restricted T-cell Epitopes in humans from the SARS-Cov-2 Spike glycoprotein antigen.		From the IEDB home page, search for MHC I restricted T-cell Epitopes in humans from the SARS-Cov-2 Spike glycoprotein antigen.

22145 Immunological Bioinformatics Course Programme Fall 2026

Carol — Thu, 27 Aug 2026 12:37:03 GMT

Exam

Show changes

22145 - Recent changes [en]

IEDB

22145 Immunological Bioinformatics Course Programme Fall 2026